Chemours Company (The) (CC) Shares Bought by Scopus Asset Management L.P.

Scopus Asset Management L.P. increased its stake in Chemours Company (The) (NYSE:CC) by 575.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 540,000 shares of the specialty chemicals company’s stock after buying an additional 460,000 shares during the period. Scopus Asset Management L.P. owned 0.29% of Chemours Company (The) worth $20,790,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the company. Ropes Wealth Advisors LLC raised its stake in Chemours Company (The) by 82.4% in the first quarter. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock valued at $119,000 after buying an additional 1,400 shares in the last quarter. Schroder Investment Management Group bought a new stake in Chemours Company (The) during the first quarter valued at about $156,000. Cypress Capital Management LLC WY raised its stake in Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock valued at $162,000 after buying an additional 80 shares in the last quarter. Clean Yield Group bought a new stake in Chemours Company (The) during the first quarter valued at about $167,000. Finally, United Capital Financial Advisers LLC bought a new stake in Chemours Company (The) during the first quarter valued at about $203,000. Institutional investors own 75.01% of the company’s stock.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Shares of Chemours Company (NYSE:CC) traded down 0.89% during mid-day trading on Friday, hitting $36.70. 4,589,490 shares of the stock traded hands. The firm has a market capitalization of $6.77 billion, a P/E ratio of 64.16 and a beta of 3.55. Chemours Company has a one year low of $5.82 and a one year high of $46.02. The company’s 50 day moving average is $41.29 and its 200 day moving average is $32.83.

Chemours Company (The) (NYSE:CC) last released its quarterly earnings results on Monday, May 1st. The specialty chemicals company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.25. Chemours Company (The) had a net margin of 1.91% and a return on equity of 125.69%. The business had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period last year, the firm earned $0.06 earnings per share. Chemours Company (The)’s revenue for the quarter was up 10.8% compared to the same quarter last year. On average, equities analysts expect that Chemours Company will post $3.27 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 15th. Investors of record on Wednesday, May 17th were given a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date was Monday, May 15th. Chemours Company (The)’s dividend payout ratio is 22.22%.

ILLEGAL ACTIVITY WARNING: This news story was posted by WKRB News and is the property of of WKRB News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.wkrb13.com/markets/2229055/chemours-company-the-cc-shares-bought-by-scopus-asset-management-l-p.html.

Several analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a research report on Thursday, February 16th. Susquehanna Bancshares Inc upgraded shares of Chemours Company (The) from a “neutral” rating to a “positive” rating and set a $40.00 price target on the stock in a research report on Friday, February 17th. Citigroup Inc. upgraded shares of Chemours Company (The) from a “neutral” rating to a “positive” rating and raised their price target for the stock from $26.00 to $40.00 in a research report on Friday, February 17th. Jefferies Group LLC restated a “buy” rating and issued a $48.00 price target on shares of Chemours Company (The) in a research report on Friday. Finally, ValuEngine upgraded shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Chemours Company (The) has a consensus rating of “Buy” and a consensus price target of $42.00.

In other Chemours Company (The) news, insider Paul Kirsch sold 19,036 shares of the stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $41.42, for a total transaction of $788,471.12. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Erich Parker sold 4,908 shares of the stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,725 shares of company stock worth $1,919,300. 1.14% of the stock is owned by insiders.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229055/chemours-company-the-cc-shares-bought-by-scopus-asset-management-l-p.html

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.